Skip to Main Content

Fate Therapeutics said Friday that an experimental, off-the-shelf immunotherapy made from so-called natural killer cells induced complete tumor responses in just over half of the patients with advanced lymphoma treated in an early-stage clinical trial.

The 56% complete response rate reported for the Fate cancer treatment, called FT516, is still preliminary — and assessed from just 11 patients — but it is similar to efficacy reported with other types of cell therapy. However, the durability of the response to FT516 remains an important, unanswered question.


The new data on FT516 were presented Friday at the annual meeting of the American Society of Clinical Oncology.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!